Clinical Trial Update: A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study of SHR-1819 injection in adults with moderate to severe atopic dermatitis has completed, with a status update provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• SHR-1819

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Moderate to Severe Atopic Dermatitis | Phase 2 | Status: COMPLETED